"Our patent application for NM504 and the establishment of our SAB are important milestones for NuMe Health as we work to accelerate the development and launch of our first cobiotic product," said Dean P. Stull, PhD, chief executive officer of NuMe Health. "NM504 is intended to provide a safe, effective and clinically validated option for the millions people at risk of developing diabetes."
Dr. Stull continued, "We are very pleased to welcome the members of our Scientific Advisory Board to the NuMe team. We expect this diverse group of distinguished advisors will provide valuable guidance as we advance NM504 and our pipeline of novel cobiotic products that leverage our expanding knowledge of how the human microbiome affects human health and disease."
NuMe's cobiotics are designed to encourage healthy bacteria, discourage unhealthy bacteria and create a healthy GI environment. Cobiotics are combinations of food components that we cannot digest but that act to control the GI microbiota and its environment in specific beneficial ways. Cobiotics also contain other components to help provide an optimal GI environment conducive for health.
NuMe's initial cobiotic products are derived from bioactive ingredients in edible plants that promote the growth of specific beneficial bacteria with the potential to positively affect metabolic conditions. NuMe's cobiotic products are evidence-based and are being developed using rigorous scientific methods, including human clinical studies, to assess and validate their health claims.
About NuMe HealthNuMe Health is a biotechnology company that intends to develop a
|SOURCE NuMe Health|
Copyright©2010 PR Newswire.
All rights reserved